Search
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … Efanesoctocog alfa (BIVV001) is a recombinant factor VIII (FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and on-demand treatment and control of bleeding
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigational[A236344] Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. … Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent.
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalPimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. … [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDesflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalIt was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesProducts: Desfluran Piramal 100 % (v/v) Flüssigkeit zur Herstellung eines Dampfs zur InhalationMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseFecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalgiven an antibacterial treatment for recurrent CDI. … Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients
Synonyms: Fecal Microbiota for TransplantEthanolamine oleate
go.drugbank.com/drugs/DB06689ApprovedEthanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Categories: Sclerosing Agents for Local InjectionIcosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIt is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Magaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Categories: Drugs for Acid Related Disorders